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ABSTRACT Nucleotide-excision repair is the repair sys-
tem for removing bulky lesions from DNA. Humans deficient
in this repair pathway suffer from xeroderma pigmentosum
(XP), a disease characterized by photodermatoses, including
skin cancers. At the cellular level, XP patients fail to remove
cyclobutane pyrimidine dimers and pyrimidine(6-4)pyrimi
done photoproducts induced byUV light, as well as other bulky
DNA lesions caused by various genotoxic agents. XP cells are
not particularly sensitive to ionizing radiation or to alkylating
agents that cause mostly nonbulky DNA lesions. Therefore, it
has generally been assumed that the human nucleotide-excision
repair enzyme (excinuclease) is specific for bulky adducts. To
determine the substrate range of human excinuclease we used
the highly sensitive excision assay and tested bulky adducts,
synthetic apurinic/apyrimidinic sites, N6-methyladenine, 06-
methylguanine, and mismatches as potential substrates. We
found that all of these "lesions" were removed by human
excinuclease, although with vastly different efficiencies.
Damage to DNA is repaired by three general mechanisms:
direct repair, base-excision repair, and nucleotide-excision
repair (1, 2). In addition to these repair systems, which act on
modified (damaged) DNA, there are repair systems that
correct mismatches generated by replication and recombina-
tion and employ base- and nucleotide-excision enzyme sys-
tems entirely different from those used in repairing damaged
DNA (see ref. 3).
In nucleotide-excision repair, an excinuclease system
made up of multiple subunits removes bulky adducts from
DNA in an oligonucleotide. Cells from xeroderma pigmen-
tosum (XP) patients that are deficient in nucleotide-excision
repair are not particularly sensitive to methylating agents or
ionizing radiation, which produce mostly nonbulky lesions.
Similarly, nucleotide-excision repair mutants carry out nor-
mal mismatch correction by mismatch-specific or general
mismatch-repair systems (3). Thus, nucleotide-excision re-
pair has generally been assumed to play no role in the cellular
response to ionizing radiation, damage by methylating
agents, or removal of a mismatched nucleotide. However, a
back-up role for nucleotide-excision repair in repairing these
lesions has not been excluded. In fact, it has been found that
the Escherichia coli excision-repair enzyme, the (A)BC ex-
cinuclease, removes 06-methylguanine (06-mG) (4, 5), apu-
rinic/apyrimidinic (AP) sites, and thymine glycols (6, 7) with
moderate efficiency. In this study, we have investigated the
susceptibility of various DNA lesions to human excinuclease
to gain further insight into the damage-recognition mecha-
nism of this enzyme and the role this repair mechanism might
play in protecting cells from nonbulky lesions and in pre-
venting mutations caused by replication errors.
MATERIALS AND METHODS
Materials. The human cell lines HeLa S3 (wild type) and
GM08437A (XP-F), and the Chinese hamster ovary cell line
CHO-UV135 (XP-G) were obtained from the Lineberger
Comprehensive Cancer Center (University of North Caroli-
na), NIGMS Human Mutant Cell Repository (Coriell Insti-
tute, Camden, NJ), and the American Type Culture Collec-
tion repository, respectively. T4 DNA ligase and polynucle-
otide kinase were purchased from Boehringer Mannheim;
['-32P]ATP (7000 Ci/mmol; 1 Ci = 37 GBq) was obtained
from DuPont/New England Nuclear. Dodecanucleotides
containing 2-aminobutyl-1,3-propanediol (ABPD; "synthetic
AP site"), 06-mG, N6-methyladenine (N6-mA), or a uracil,
as well as unmodified oligomers 14-64 nt in length, were
purchased from Operon Technologies (Alameda, CA). The
dodecamers containing thymine monoadduct of 4'-hydroxy-
methyl-4,5',8-trimethylpsoralen (T-HMT) and cisplatin [cis-
diamminedichloroplatinum (II)] 1,2-d(GpG) crosslink were
from J. E. Hearst (University of California, Berkeley) and
S. J. Lippard (Massachusetts Institute of Technology), re-
spectively.
Substrates. The substrates were 156-bp duplexes obtained
by ligating the terminally labeled dodecamer containing the
lesion with seven other partially overlapping oligomers as
described (8, 9). The sequence of the modified oligomer is
5'-Gl A2 A3 G4 C5 T6 A7 C8 G9 A10 G1 C12-3'. Derivatives of
this oligomer contained the lesion T6-HMT for psoralen
monoadduct, 06-mG at position 4, N6-mA at position 7,
ABPD instead ofT6 for "synthetic AP," as well as adenine
at position 5 for A*-G mismatch, guanine at position 5 for
G*-G mismatch, and guanine at position 6 for G*.A mismatch
(asterisk indicates radiolabeling). The dodecamer containing
the cisplatin-1,2-d(GpG) diadduct had the sequence TCTAG-
GCCTTCT (10).
Enzyme Systems. Cell-free extract (CFE) prepared by the
method of Manley et al. (11) was the source of mammalian
excinuclease. The UvrA, UvrB, and UvrC subunits ofE. coli
(A)BC excinuclease were prepared as described (12). In both
systems the assays were conducted under saturating enzyme
conditions.
Repair Assay. The "excision assay" (13) was used to
measure the susceptibility of various substrates for human
and E. coli excinucleases. The substrates, depending on the
location of the lesion relative to the 5' terminus of the
modified dodecamer, contained 32p label at the 4th, 5th, or
6th phosphodiester bond 5' to the lesion. Thus, removal of
the lesion by E. coli (A)BC excinuclease releases radiola-
beled 12- to 13-nt-long oligomers, and the human excinu-
clease releases 27- to 29-nt-long oligomers. The reaction with
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human excinuclease was done as follows. The reaction
mixture (25 1Ld) contained 40mM Hepes (pH 7.9), 80mM KCl,
8 mM MgCl2, 2 mM ATP, 20 AuM of each dNTP, 1 mM
dithiothreitol, 7% (vol/vol) glycerol, bovine serum albumin
at 200 pg/ml, 50 Mg of CFE, and 0.4-1.9 nM substrate, as
indicated. The reaction was done at 300C for 15-120 min as
indicated. After deproteinization (13), the products were
precipitated with ethanol and separated on 10% or 12%
polyacrylamide sequencing gels. The (A)BC excinuclease
reaction was conducted as follows. The reaction mixture (25
,ul) contained 50 mM Tris HC1 (pH 7.5), 100 mM KCl, 10mM
MgCl2, 2 mM ATP, 1 mM dithiothreitol, 5 nM UvrA, 80 nM
UvrB, 40 nM UvrC, 0.07 nM pBR322, and 0.8 nM substrate.
Mixtures were incubated at 37°C for 30 min. The reaction was
stopped by adding EDTA to 100 mM, and the products were
separated on 12% polyacrylamide. The level of excision was
quantified by an AMBIS scanner (AMBIS Systems, San
Diego). The region corresponding to 15-20 nt inE. coli assays
and 35-40 nt in human excinuclease assays was taken as
background. The fraction of radiolabel in these areas, which
is assumed to represent nonspecific degradation, varied from
0.01 to 0.05%.
RESULTS
Substrates. DNA fragments containing a lesion 60 nt from
the 5' terminus and 44 nt from the 3' terminus of the damaged
strand are efficient substrates for the human excinuclease (9).
Thus, our basic design for substrate consisted of ligating a
dodecamer carrying a lesion (or a mismatch) with seven other
oligomers to obtain a 156-bp duplex in which the lesion is 92
nt away from the 5' end and 62 nt away from the 3' end (Fig.
1). Four types of substrates known to be repaired primarily
by one of the four major repair systems were tested: 06-mG
(direct repair), AP site (base-excision repair), T-HMT and
cisplatin 1,2-d(GpG) diadduct (nucleotide-excision repair),
and single-base mismatches G-A, A-G, and GG (mismatch
repair). In addition, N6-mA was tested because, even though
this is a natural base in E. coli, it is not a normal constituent
ofhuman DNA. The structures ofthese various "lesions" are
shown in Fig. 2.
Excision ofAP Site. Because an AP site is excised by the E.
coli (A)BC excinuclease (6, 7) relatively efficiently, we
initially tested the human excinuclease with an AP substrate
generated by releasing a site-specifically incorporated uracil
by uracil glycosylase. The AP site generated by this method
was excised by human excinuclease in 27- to 29-mers (data
not shown). However, because of the very potent AP endo-
nuclease in the human CFE, the substrate was extensively
degraded, generating high background superimposed over
the relatively weak signal. We decided to use a "synthetic
AP" that is less susceptible to AP endonucleases. We chose
to use DNA containing ABPD. The propanediol part of this
compound maintains the natural 3-carbon internucleotide
phosphate distance like the deoxyribose in phosphodiester




FIG. 2. Structures of DNA duplex alterations that constitute
substrates for human excinuclease. T<>Pso, T-HMT.
ring-opened deoxyribose (14). When tested with human CFE,
this structure was excised quite efficiently. To demonstrate
that this excision was done by the human excinuclease, as
defined by the UV-sensitive human and rodent mutant cell
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FIG. 1. Substrate construction. The central 12-nt oligomer (G), either unmodified or modified at positions 4, 5, or 6, was terminally labeled
with 32P and ligated with seven other oligomers (A, B, C, D, E, F, and H) to obtain the 156-bp duplex. The diamond indicates position of the
T-HMT adduct or the "synthetic AP"; the asterisk indicates position ofthe radiolabel. The main incision sites ofhuman and E. coli excinucleases
relative to the modification at position 6 (diamond) and the sizes of the excised fragment are indicated by brackets.
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different mutants (15). The result is shown in Fig. 3. CFE
from cell lines with mutations in XPF or XPG genes did not
excise 27- to 29-nt-long oligomers. However, mixing the two
CFEs restored excision activity comparable to that seen with
HeLa CFE (Fig. 3, lanes 3 and 4). Thus, we conclude that
human excinuclease excises the "synthetic AP site" by the
standard dual-incision mechanism.
To evaluate the relative affinity of human excinuclease for
synthetic AP compared with the traditional nucleotide exci-
sion-repair substrates, we conducted excision assays with the
synthetic AP duplex and with a substrate containing 1,2-
d(GpG) cisplatin adduct, which is eliminated from DNA
exclusively by excision repair at a rate comparable to cy-
clobutane pyrimidine dimer (9, 10). Fig. 4 shows that the two
lesions are excised with comparable efficiencies with a rate
of75 fmol/min for synthetic AP and 30 fmol/min for cisplatin
1,2-d(GpG) crosslink under identical experimental condi-
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FIG. 3. Removal of synthetic AP (ABPD) requires functional
excinuclease. The substrate (54 pM) with ABPD at position 6 of the
central oligomer was incubated with CFE from XP-F (F) orXP-G (G)
cell lines, a mixture of the two (FG), or HeLa (H) CFE. Reaction
mixtures contained 100 pg of total protein, and incubation was for 1
hr at 300C (M, 30-nt-long marker). The high nonspecific degradation
seen in XP-F is uncharacteristic of this cell line but typical of this
particular CFE.
FIG. 4. Comparison ogrelative affinities of synthetic AP (ABPD)
and cisplatin diadduct ( A ) to human excinuclease. Reaction mix-
tures containing 54 pM substrate and 100 Pg of HeLa CFE, which
were incubated for 5 (anes 1 and 7), 10 (lanes 2 and 8), 20 (lanes 3
and 9), 40 (lanes 4 and 10), 60 (lanes 5 and 11), and 90 min (lanes 6
and 12). Maximum excision for ABPD was 3.91% at 40 min, and
maximum excision for 1,-d(GpG) cisplatin crosslink was 3.3% at 90
min (M, 30-nt-long marker).
human excinuclease, and because ofits ready availability, we
used it as a reference substrate for other lesions tested.
Excision of Methylated Bases. 06-mG is a mutagenic lesion
that causes G(C -> ART transition (16). This lesion is elimi-
nated from DNA by the suicide enzyme, 06-mG-DNA meth-
yltransferase. It has been reported that in Mer- or Mex-
mammalian mutants lacking the enzyme (17, 18), the level of
06-mG does not change detectably (19), suggesting that
06-mG is not a substrate for human excinuclease. However,
these experiments lack the resolution to detect a low level of
removal by nucleotide-excision repair. Fig. 5 shows that
06-mG is removed by the same enzyme system that removes
bulky adducts both in E. coli (lane 3) and humans (lane 7).
However, the extent of excision is low compared with the
synthetic AP: --15% relative to synthetic AP in both systems.
In contrast to 06-mG, N6-mA, which is found in prokaryotic
but not eukaryotic DNA, is excised by the human excinu-
clease (lane 6) but not by the prokaryotic excinuclease (lane
2).
Excision of Mismatches. Do excision nucleases also act on
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FIG. 5. Removal of methylated bases by E. coli and human
excinucleases. Lanes: 1 and 5, unmodified DNA (UM); 2 and 6,
N6-mA (N6); 3 and 7, 06-mG (06); 4 and 8, synthetic AP; M,
30-nt-long size marker. DNA concentrations in all reactions were
-0.5 nM, and reactions were for 30 min at 37rC for (A)BC excinu-
clease and for 1 hr at 30TC for HeLa CFE. Results from different gels
were combined for presentation. Levels of excision were as follows:
lanes 1, 2, and 5, nondetectable; lane 3, 1% (note 06-mG is removed
in 11-nt-long fragment in this sequence context); lane 4, 5%; lane 6,
0.06%; lane 7, 0.1%; lane 8, 1%.
involving purine-purine mismatches yielded easily detect-
able signals; thus, we concentrated our studies on three
mismatches. Fig. 6, lanes 2 and 8 show that the guanine in a
G-A mismatch is excised by the excision-repair systems of
both E. coli and humans. With human CFE and in this
sequence context, the guanine strand of the G'A mismatch
was excised 2-fold more than the adenine strand (Fig. 6,
lanes 8 and 9) which in turn is "repaired" better than the
mismatch in GIG (lanes 9 and 10). In E. coli also the guanine
strand in the G-A mismatch was excised more efficiently than
the adenine strand (lanes 2 and 3), and the G-G mismatch was
also excised relatively efficiently (lane 4). All mismatches
tested were repaired to a lesser extent than synthetic AP or
FIG. 6. Removal of mismatches, AP sites, and T-HMT adduct by
excision nucleases. Lanes: 1 and 7, unmodified (UM) DNA; 2 and 8,
G*.A mismatch (guanine strand labeled); 3 and 9, A*.G mismatch; 4
and 10, G*<G mismatch; 5 and 11, AP site; 6 and 12, T-HMT. All
substrates were at -1.0 nM in 25-pJ reaction mixtures. Incubation
conditions were as for Fig. 5. Levels ofexcision were as follows: lane
1, not detectable; lane 2, 0.3%; lane 3, 0.05%; lane 4, 0.1%; lane 5,
2%; lane 6, 85% (only 10%o of the DNA was loaded onto the gel); lane
7, not detectable; lane 8, 0.2%; lane 9, 0.1%; lane 10, 0.05%; lane 11,
5%; lane 12, 1%. The low-molecular-weight species seen in lanes
7-12 are generated by nonspecific nucleases in the CFE.
psoralen monoadducts. The low extent of mismatch repair
(0.05-0.3% of substrate) precluded a systematic analysis of
repair rates of the entire set of mismatches and the effects of
sequence context on strand preference. However, as data in
Fig. 6 show, we obtained clear evidence that both E. coli and
human excinucleases preferred mismatches over unmodified
DNA and that, at least in one case, the excinucleases
preferred one strand over the other in a duplex with a
mismatch.
Comparative Analysis of Human and E. cofi Excinucleases.
The data presented so far indicate that human and E. coli
excinucleases have the same range of substrates. However,
their substrate preferences are quite different, as is seen most
clearly in Fig. 6, which shows a direct comparison of sub-
strate preference of these two enzyme systems. The E. coli
excinuclease excises the T-HMT at -50-fold faster rate than
the synthetic AP site (lanes 5 and 6). In contrast, the extent
of repair of synthetic AP by human excinuclease is =10-fold
higher than that for T-HMT (lanes 11 and 12). Thus, even
though the two enzyme systems excise almost all modified
1 x A.-C~
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bases from DNA, they do so with vastly different prefer-
ences.
DISCUSSION
In both pro- and eukaryotes, nucleotide-excision repair is the
repair system for bulky adducts (2, 20, 21). In E. coli this
repair system was reported (2) to be active on all unnatural
base modifications tested. Our study reveals that the same is
also true for the human excinuclease system. How the same
enzyme system recognizes base modifications ranging from
N6-mA to thymine dimer is an interesting question. A plau-
sible answer is as follows. The recognition subunits of the
enzyme bind to DNA nonspecifically with relatively high
affinity. The binding induces certain conformational changes,
such as kinking and unwinding at the binding site. If a given
site is more prone to undergo such a conformational change
because of the base modification, a higher affinity interaction
ensues, and this long-lived complex then becomes a target for
the nuclease subunits that bind to the recognition complex
and induce the double incision (2). Implicit in this model is the
hypothesis that excinucleases should, to a limited degree,
also act on unmodified DNA. Indeed, evidence for such
action in the case of E. coli (A)BC excinuclease has been
obtained (22, 23). Although it is rather difficult to eliminate
the possibility that the low level of excision seen with
nominally undamaged DNA is, in fact, due to the low level of
lesions resulting from handling and radiolabeling of the
control substrate, long exposures of our autoradiographs of
"undamaged DNA" treated with human excinuclease reveal
low levels of 27- to 29-mers superimposed on the ladder,
resulting from random degradation of DNA. In light of our
current findings, we believe that low level of excision does
occur, even on undamaged DNA.
The different substrate preferences of the human and E.
coli excinucleases suggest substantially different recognition
mechanisms. N6-mA, which is found at a relatively high
frequency in E. coli, is not a substrate for the E. coli enzyme
but is excised by the human excinuclease. This result sug-
gests that excinucleases have evolved to accommodate the
base modifications found in those particular organisms as
normal and others as a lesion. Indeed, expression of the Dam
methylase in Saccharomyces cerevisiae (which normally
does not contain N6-mA) induced single-strand breaks that
depended on an intact nucleotide-excision repair system (24),
consistent with the hypothesis that the yeast excision-repair
system, which resembles the human system (20), also excises
N6-mA.
The differential recognition mechanisms are also reflected
in the substrate preference of E. coli and human excinu-
cleases. There is a dramatic difference between the human
and E. coli enzymes with regard to their effects on the
synthetic AP substrate and the T-HMT, the human enzyme
being more active on the former and the E. coli enzyme being
more active on the latter. The differential substrate prefer-
ence is not that surprising, considering the fact that the
human and E. coli excision-repair subunits do not share
homology. From a practical standpoint, these results suggest
that caution must be exercised in extrapolating from pro-
karyotic model systems to humans with regard to repairabil-
ity and, hence, mutagenic and cytotoxic effects of a given
lesion.
The findings reported here also raise some questions
regarding the role of excision repair in resistance to oxidative
damage, methylating agent, and in correcting mismatches.
Human XP cells (25) and their rodent counterparts (26) are
exquisitely sensitive to UV light and not particularly sensitive
to ionizing radiation or alkylating agents. We believe that
excision repair plays mainly a back-up role for glycosylase
and AP endonucleases (27) responsible for repairing the
damage of the latter agents, consistent with reports that the
contribution of excision repair can be seen only in an appro-
priate E. coli background (28).
Finally, mismatch "correction" by excinucleases is quite
inefficient compared with the Mut(H)LS-dependent mis-
match-correction system (29, 30); an earlier study using the
less sensitive nicking assay failed to detect the effect of
(A)BC excinuclease on mismatches (31). From a physiolog-
ical standpoint, while the mismatch repair system can dis-
criminate between correct and incorrect strands by the
presence of a nick in the incorrect strand, no evidence
suggests that the excinuclease has such a capability. Rather,
the excinuclease appears to excise the mismatch from one or
the other strand, as dictated by the structure ofthe particular
mismatch. Thus, nucleotide-excision repair could cause mu-
tation fixation by actually interfering with the mismatch
correction of the Mut(H)LS system, rather than help in
mutation avoidance. Whether this activity plays a role in
spontaneous mutation rate in vivo remains to be seen.
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